THE ROLE OF MONOCLONAL ANTIBODY IN THE MANAGEMENT OF PROSTATE ADENOCARCINOMA

Abstract

The monoclonal antibody conjugate ProstaScint provides additional information in detection and localization of recurrent prostate cancer and would be helpful in the selection of patients for subsequent external beam radiation therapy.